Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
BUSINESS
Takeda’s Cell Therapy Alofisel Approved in Japan
Takeda Pharmaceutical said on September 27 that it has obtained Japanese regulatory approval for its cell therapy Alofisel (darvadstrocel) for the treatment of complex perianal fistulas in patients with non-active or mildly active luminal Crohn’s disease. Alofisel, also known as…
To read the full story
Related Article
- Takeda Rolls Out Crohn’s Disease Cell Therapy Alofisel in Japan
December 1, 2021
- Takeda’s GI Biz Poised for Growth with 3 Products Now in Its Lineup
November 29, 2021
- Takeda’s Cell Therapy Alofisel Gets 5.62 Million Yen Price Tag
November 17, 2021
- Drug Pricing Rules to Be Applied to Takeda’s Cell Therapy Alofisel: Chuikyo
October 14, 2021
- Takeda’s 1st Cell Therapy Up for PAFSC Review on Sept. 6
August 24, 2021
BUSINESS
- Vimpat Copies Hit Shelves at 35% of Originator Price as 10 Firms Flock to Market
December 5, 2025
- Forxiga Generics Launch in Japan at 33.6% of Originator Price: Sawai, T’s Pharma
December 5, 2025
- Eylea Bio-AG to Carry DME Indication Missing from Fuji’s Biosimilar Label
December 5, 2025
- Keytruda Extends Japan Sales Lead to 26 Straight Months in November: Encise
December 5, 2025
- Novo Nordisk Launches Higher-Capacity Awiqli Pen in Japan
December 4, 2025
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s drug pricing panel on November 19 discussed a wide range of potential pricing changes related to patent-protected medicines, including…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…